Simulation Model of Ibrutinib in Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Value Health
.
2014 Nov;17(7):A620.
doi: 10.1016/j.jval.2014.08.2196.
Epub 2014 Oct 26.
Authors
S Peng
1
,
S Sorensen
1
,
F Pan
1
,
E Dorman
1
,
S Sun
2
,
S Van Sanden
3
,
N Sengupta
4
,
M Gaudig
5
Affiliations
1
Evidera, Bethesda, MD, USA.
2
Janssen, Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ, USA.
3
University Hospital Leuven, Leuven, Belgium.
4
Janssen Pharmaceuticals, Inc, Raritan, NJ, USA.
5
Janssen Pharmaceuticals, Inc, Neuss, Germany.
PMID:
27202180
DOI:
10.1016/j.jval.2014.08.2196
No abstract available